BRAF and melanoma: Here, we strengthened this observation by using alternative murine (D4M.3A, B2905, B16F10) and human (131/4-5B1, A375, WM115) melanoma models and clinical samples that present different origins, mutations (BRAF, PTEN, etc.), and responsiveness to immunotherapy.